Publications
- Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis2023 | First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data2022 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University, Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy2022 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice2021 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data2021 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma2021 | Faculty of Medicine in Hradec Králové
- Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data2020 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies2019 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia2019 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population2019 | Publication without faculty affiliation
Loading network view...